VST BIO Corp filed an amended Form D with the Securities and Exchange Commission on 2025-11-18.
VST BIO Corp filed an amended Form D notice of an exempt securities offering with the SEC on November 18, 2025. The filing reports $31.89M sold. Its industry group is Pharmaceuticals. It names Krisztina Zsebo (Executive Officer, Director), Rebecque Laba (Executive Officer), David Cheresh (Director) (SEC Form D/A, November 18, 2025).
Is this your company?
Sell to companies like VST BIO Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-11-18 · the record
Pitching, partnering or investing alongside them? See who really runs and owns VST BIO Corp.
Free to see. No signup.
More on the people and the money behind VST BIO Corp, from the filings we hold.
Pharmaceuticals raises by companies based in California, filed in November 2025, largest first.
Get an email when VST BIO Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when VST BIO Corp raises, hires or launches. No email unless you switch it on.
Watch VST BIO Corp →Get the full cited report on VST BIO Corp
What the filing shows about VST BIO Corp
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on VST BIO Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives VST BIO Corp's address as 4653 Carmel Mountain Road, Ste 308, Pmb 1015, San Diego, CA 92130.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for VST BIO Corp →
Amended on 2026-04-24: the offering size changed from $28,888,146 to $31,888,146; the amount sold changed from $28,888,146 to $31,888,146. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
VST BIO Corp is a registered filer with the SEC (CIK 2093250) and has filed since 2025-11-18. 1 filing is on record, the latest on 2025-11-18.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
VST BIO Corp's Form D of 2025-11-18 names Krisztina Zsebo, Rebecque Laba, David Cheresh and 2 more as its officers, directors or promoters.
Its new offerings report $28.89M sold across 1 offering, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week. The dot is this raise, $31.89M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Krisztina Zsebo is named as Executive Officer and Director on the Form D that VST BIO Corp filed with the SEC on 18 November 2025, one of 6 people that filing names.
Rebecque Laba is named as Executive Officer on the Form D that VST BIO Corp filed with the SEC on 18 November 2025, one of 6 people that filing names.
David Cheresh is named as Director on the Form D that VST BIO Corp filed with the SEC on 18 November 2025, one of 6 people that filing names.
J. Ware is named as Director on the Form D that VST BIO Corp filed with the SEC on 18 November 2025, one of 6 people that filing names.
Chris Somerville is named as Director on the Form D that VST BIO Corp filed with the SEC on 18 November 2025, one of 6 people that filing names.
William Sessa is named as Director on the Form D that VST BIO Corp filed with the SEC on 18 November 2025, one of 6 people that filing names.
6 people named on the filing — 2 holding an executive role and 4 as directors only.
Named as of the 2025-11-18 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about VST BIO Corp
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on VST BIO Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on VST BIO Corp covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist VST BIO CorpYou get an alert in MentionFox the next time this company shows up.
If you're behind VST BIO Corp: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for VST BIO Corp. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in San Diego
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/vst-bio-corp-form-d-25000001